May 4, 2022 10:49 AM EDT

BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

BerGenBio said it will prioritize its pipeline to focus on first-line non-small cell lung cancer and Covid-19 with its lead drug bemcentinib. That means work …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

BerGen­Bio nar­rows R&D to fo­cus on NSCLC and Covid-19; Oral SERDs see an­oth­er set­back as G1 drops pro­gram

Senior Reporter

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program